Meb Corp Public Company Limited logo

Meb Corp Public Company Limited (MEB.R)

Market Closed
11 Aug, 23:30
SET SET
฿
12. 70
-0.2
-1.5504%
฿
- Market Cap
- P/E Ratio
- Div Yield
195,900 Volume
- Eps
฿ 12.9
Previous Close
Add Transaction
Day Range
12.7 12.9
Year Range
11.2 19.7
Want to track MEB.R and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

MEB.R closed today lower at ฿12.7, a decrease of -1.5504% from yesterday's close, completing a monthly increase of 2.4194% or ฿0.3. Over the past 12 months, MEB.R stock lost -23.0303%.
MEB.R is not paying dividends to its shareholders.
The last earnings report, released on Sep 30, 2016, missed the consensus estimates by -0.05%. On average, the company has fell short of earnings expectations by -0.03%, based on the last three reports.
Meb Corp Public Company Limited has completed 3 stock splits, with the recent split occurring on Oct 23, 2023.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ASX (AUD).

MEB.R Chart

Meb Corp Public Company Limited (MEB.R) FAQ

What is the stock price today?

The current price is ฿12.70.

On which exchange is it traded?

Meb Corp Public Company Limited is listed on SET.

What is its stock symbol?

The ticker symbol is MEB.R.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Meb Corp Public Company Limited ever had a stock split?

Meb Corp Public Company Limited had 3 splits and the recent split was on Oct 23, 2023.

Meb Corp Public Company Limited Profile

Insurance Industry
Financials Sector
Dr. Thomas Richard Young M.D. CEO
SET Exchange
AU000000MEB8 ISIN
Australia Country
- Employees
- Last Dividend
23 Oct 2023 Last Split
- IPO Date

Overview

Medibio Limited is a pioneering health technology company operating out of Mount Lawley, Australia, with its efforts focused on the international stage, particularly in Australia and the United States. The company's mission revolves around the advancement of diagnostic and screening techniques for mental health conditions. Initially established under the name BioProspect Limited in 1987, it underwent a significant transformation, rebranding to Medibio Limited in November 2014. This rebranding marked the company's strategic pivot towards mental health technologies, reinforcing its commitment to addressing the challenges within this critical domain of healthcare.

Products and Services

Medibio Limited has developed a suite of innovative products and services designed to support mental well-being in various contexts, each tailored to meet the diverse needs of its users:

  • Corporate Health Product: This offering is targeted towards businesses seeking to enhance the mental wellness of their workforce. Medibio's corporate health product leverages cutting-edge technology to provide companies with tools for effective mental health screening and management among employees. The objective is to foster a healthier work environment, reduce absenteeism, and contribute positively to overall productivity and employee satisfaction.
  • Healthcare Provider Market Products: In addition to its corporate solutions, Medibio is also developing products specifically designed for the healthcare provider market. These tools aim to revolutionize the diagnosis and treatment of mental health conditions by offering more precise and reliable screening processes. By facilitating early detection and intervention, Medibio seeks to significantly improve patient outcomes, offering healthcare professionals breakthrough solutions in the management of mental health disorders.

Contact Information

Address: 647 Beaufort Street
Phone: 61 8 6189 1155